Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Y-mAbs Therapeutics, Inc. (YMAB : NSDQ)
 
 • Company Description   
Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.

Number of Employees: 107

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.30 Daily Weekly Monthly
20 Day Moving Average: 197,003 shares
Shares Outstanding: 45.28 (millions)
Market Capitalization: $194.72 (millions)
Beta: 0.51
52 Week High: $16.11
52 Week Low: $3.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.69% -20.25%
12 Week -1.15% -17.07%
Year To Date -45.08% -48.56%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
202 Carnegie Center Suite 301
-
PRINCETON,NJ 08540
USA
ph: 646-885-8505
fax: -
cdu@ymabs.com http://www.ymabs.com
 
 • General Corporate Information   
Officers
Michael Rossi - Chief Executive Officer;President and Director
Peter Pfreundschuh - Chief Financial Officer and Treasurer
Thomas Gad - Director
Johan Wedell-Wedellsborg - Director
Laura J. Hamill - Director

Peer Information
Y-mAbs Therapeutics, Inc. (CORR.)
Y-mAbs Therapeutics, Inc. (RSPI)
Y-mAbs Therapeutics, Inc. (CGXP)
Y-mAbs Therapeutics, Inc. (BGEN)
Y-mAbs Therapeutics, Inc. (GTBP)
Y-mAbs Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 984241109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/11/25
Share - Related Items
Shares Outstanding: 45.28
Most Recent Split Date: (:1)
Beta: 0.51
Market Capitalization: $194.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.97 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 43.63% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.18
Price/Cash Flow: -
Price / Sales: 2.20
EPS Growth
vs. Year Ago Period: 20.00%
vs. Previous Quarter: 20.00%
Sales Growth
vs. Year Ago Period: 4.88%
vs. Previous Quarter: -21.10%
ROE
06/30/25 - -
03/31/25 - -30.59
12/31/24 - -31.31
ROA
06/30/25 - -
03/31/25 - -22.70
12/31/24 - -23.35
Current Ratio
06/30/25 - -
03/31/25 - 4.77
12/31/24 - 4.16
Quick Ratio
06/30/25 - -
03/31/25 - 4.35
12/31/24 - 3.85
Operating Margin
06/30/25 - -
03/31/25 - -31.84
12/31/24 - -33.83
Net Margin
06/30/25 - -
03/31/25 - -31.84
12/31/24 - -33.83
Pre-Tax Margin
06/30/25 - -
03/31/25 - -32.18
12/31/24 - -34.00
Book Value
06/30/25 - -
03/31/25 - 1.98
12/31/24 - 2.05
Inventory Turnover
06/30/25 - -
03/31/25 - 1.91
12/31/24 - 1.78
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©